Objective To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies. Methods We conducted a multicentre, international, retrospective cohort study. Results 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included. Dermatomyositis (64, 43%) and amyopathic dermatomyositis (47, 31%), were the main diagnosis; 15 patients (10%) were classified as interstitial pneumonia with autoimmune features (IPAF) and 7 (5%) as rheumatoid arthritis. The main clinical findings observed were myositis (84, 56%), interstitial lung disease (ILD) (108, 78%), skin lesions (111, 74%), and arthritis (76, 51%). The onset of these manifestations was not concomitant in 74 cases (50%). Of note, 32 (21.5%) patients were admitted to the intensive care unit for rapidly progressive-ILD, which occurred in median 2 months from lung involvement detection, in the majority of cases (28, 19%) despite previous immunosuppressive treatment. One-third of patients (47, 32% each) was ANA and anti-ENA antibodies negative and a similar percentage was anti-Ro52 kDa antibodies positive. Non-specific interstitial pneumonia (65, 60%), organising pneumonia (23, 21%), and usual interstitial pneumonia-like pattern (14, 13%) were the main ILD patterns observed. Twenty-six patients died (17%), 19 (13%) had a rapidly progressive-ILD. Conclusion The clinical spectrum of the anti-MDA5 antibodies-related disease is heterogeneous. Rapidly-progressive ILD deeply impacts the prognosis also in non-Asian patients, occurring early during the disease course. Anti-MDA5 antibody positivity should be considered even when baseline autoimmune screening is negative, anti-Ro52 kDa antibodies are positive, and radiology findings show a NSIP pattern.

Cavagna, L., Meloni, F., Meyer, A., Sambataro, G., Belliato, M., De Langhe, E., et al. (2022). Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 40(2), 274-283 [10.55563/CLINEXPRHEUMATOL/DI1083].

Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies

Scire C. A.;Pesci A.;Luppi F.;
2022

Abstract

Objective To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies. Methods We conducted a multicentre, international, retrospective cohort study. Results 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included. Dermatomyositis (64, 43%) and amyopathic dermatomyositis (47, 31%), were the main diagnosis; 15 patients (10%) were classified as interstitial pneumonia with autoimmune features (IPAF) and 7 (5%) as rheumatoid arthritis. The main clinical findings observed were myositis (84, 56%), interstitial lung disease (ILD) (108, 78%), skin lesions (111, 74%), and arthritis (76, 51%). The onset of these manifestations was not concomitant in 74 cases (50%). Of note, 32 (21.5%) patients were admitted to the intensive care unit for rapidly progressive-ILD, which occurred in median 2 months from lung involvement detection, in the majority of cases (28, 19%) despite previous immunosuppressive treatment. One-third of patients (47, 32% each) was ANA and anti-ENA antibodies negative and a similar percentage was anti-Ro52 kDa antibodies positive. Non-specific interstitial pneumonia (65, 60%), organising pneumonia (23, 21%), and usual interstitial pneumonia-like pattern (14, 13%) were the main ILD patterns observed. Twenty-six patients died (17%), 19 (13%) had a rapidly progressive-ILD. Conclusion The clinical spectrum of the anti-MDA5 antibodies-related disease is heterogeneous. Rapidly-progressive ILD deeply impacts the prognosis also in non-Asian patients, occurring early during the disease course. Anti-MDA5 antibody positivity should be considered even when baseline autoimmune screening is negative, anti-Ro52 kDa antibodies are positive, and radiology findings show a NSIP pattern.
Articolo in rivista - Articolo scientifico
idiopathic inflammatory myopathies; melanoma differentiation-associated protein 5 antibody; rapidly progressive interstitial lung diseases;
English
274
283
10
Cavagna, L., Meloni, F., Meyer, A., Sambataro, G., Belliato, M., De Langhe, E., et al. (2022). Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 40(2), 274-283 [10.55563/CLINEXPRHEUMATOL/DI1083].
Cavagna, L; Meloni, F; Meyer, A; Sambataro, G; Belliato, M; De Langhe, E; Cavazzana, I; Pipitone, N; Triantafyllias, K; Mosca, M; Barsotti, S; Zampogna, G; Biglia, A; Emmi, G; De Visser, M; Van Der Kooi, A; Parronchi, P; Hirschi, S; da Silva, J; Scire, C; Furini, F; Giannini, M; Martinez Gonzalez, O; Damian, L; Piette, Y; Smith, V; Mera-Valera, A; Bachiller-Corral, J; Cabezas Rodriguez, I; Brandy-Garcia, A; Maurier, F; Perrin, J; Gonzalez-Moreno, J; Drott, U; Delbruck, C; Schwarting, A; Arrigoni, E; Sebastiani, G; Iuliano, A; Nannini, C; Quartuccio, L; Rodriguez Cambron, A; Blazquez Canamero, M; Villa Blanco, I; Cagnotto, G; Pesci, A; Luppi, F; Dei, G; Romero Bueno, F; Franceschini, F; Chiapparoli, I; Zanframundo, G; Lettieri, S; De Stefano, L; Cutolo, M; Mathieu, A; Piga, M; Prieto-Gonzalez, S; Moraes-Fontes, M; Fonseca, J; Jovani, V; Riccieri, V; Santaniello, A; Montfort, S; Bilocca, D; Erre, G; Bartoloni, E; Gerli, R; Monti, M; Lorenz, H; Sambataro, D; Bellando Randone, S; Schneider, U; Valenzuela, C; Lopez-Mejias, R; Cifrian, J; Mejia, M; Gonzalez Perez, M; Wendel, S; Fornaro, M; De Luca, G; Orsolini, G; Rossini, M; Dieude, P; Knitza, J; Castaneda, S; Voll, R; Rojas-Serrano, J; Valentini, A; Vancheri, C; Matucci-Cerinic, M; Feist, E; Codullo, V; Iannone, F; Distler, J; Montecucco, C; Gonzalez-Gay, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/367245
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
Social impact